Overview

Dose Ranging Study for Indacaterol in Japanese Asthma Patients

Status:
Completed
Trial end date:
2007-11-01
Target enrollment:
Participant gender:
Summary
This study was designed to provide data about the safety and efficacy of 3 doses of indacaterol (150, 300, and 600 µg) in Japanese asthma patients so that an optimal dose, or doses, could be chosen for testing in later studies.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Salmeterol Xinafoate